Expert Review Of Clinical Pharmacology

Journal Title：Expert Review Of Clinical Pharmacology

Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.

Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.

藥物開發技術的進步正在催生創新的新療法，從可能挽救生命的藥物到生活方式產品。然而，近年來，開發新藥的成本飆升，對耐藥性和藥物經濟學的擔憂也日益凸顯。臨床試驗階段的不良反應不斷提醒人們嚴格的安全性和毒性測試的重要性。此外，藥物基因組學和“個性化”治療方法的出現將要求一種新的藥物評估和醫療保健方法。

臨床藥理學在整合所有積極應對現代生物醫學實踐中此類挑戰的專家和參與者的專業知識方面發揮著重要作用。

Expert Review Of Clinical Pharmacology創刊于2008年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋PHARMACOLOGY & PHARMACY全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 ，影響因子指數3.6，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。